Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases

@article{Rossi2004HyperthermicIL,
  title={Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases},
  author={Carlo Riccardo Rossi and Mirto Foletto and Simone Mocellin and Pierluigi Pilati and Mario Lise},
  journal={Annals of Surgical Oncology},
  year={2004},
  volume={11},
  pages={173-177}
}
Background: Melphalan (L-PAM) hyperthermic isolated limb perfusion (HILP) is currently considered the standard treatment for patients with in-transit metastases from cutaneous melanoma. We here report on the results of L-PAM and low-dose tumor necrosis factor (TNF)α HILP in patients with bulky disease. Methods: Twenty patients underwent TNFα (1 mg) and L-PAM (10 mg/L) HILP. Perfusion was performed for 90 minutes, and systemic leakage was strictly monitored. Locoregional toxicity was evaluated… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

  • AH van der Veen, JH de Wilt, AM Eggermont, ST van Tiel, AL Seynhaeve, TL. ten Hagen
  • Br J Cancer 2000;82:973–80
  • 2004

A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN)

  • D Fraker, H Alexander, M Ross
  • Ann Surg Oncol 2002;9:S8
  • 2002

An open, randomized prospective trial to compare the efficacy and safety of TNFalpha 1a and melphalan with melphalan alone via isolated limb perfusion for metastatic melanoma of the limb

  • G. Steinmann
  • 2001

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

  • JH de Wilt, TL ten Hagen, G de Boeck, ST van Tiel, EA de Bruijn, AM. Eggermont
  • Br J Cancer 2000;82:1000–3
  • 2000

Similar Papers

Loading similar papers…